Visible science

Nicox develops innovative therapeutics to help maintain vision and improve ocular health

Combined Ordinary and Extraordinary Shareholder meeting of June 27, 2025

Learn more about the mechanism of action of NCX 470, our lead product candidate in glaucoma

Nicox: Notice of the Ordinary and Extraordinary Shareholders’ Meeting on June 27, 2025 and appointment of an ad hoc representative
Read more
Nicox Announces up to €3 million in Milestone Payments from Kowa in 2025 as NCX 470 Prepares to Enter Phase 3 Clinical Trials in Japan
May 27, 2025 Read more
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial
May 14, 2025 Read more